Discover the latest advancements in biosimilars, including tocilizumab's new indication, and partnerships for omalizumab and ...

The agreement is for Kashiv BioSciences’ biosimilar candidate to Genentech and Novartis AG’s Xolair (omalizumab) in the ...

Omalizumab, currently used to treat asthma, has been shown to substantially reduce the risk of potentially life-threatening reactions in people aged one and older with multiple common food ...

WASHINGTON — Patients with multiple food allergies experienced a protective effect against allergic reactions with omalizumab, according to an abstract presented at the American Academy of ...

During the first period, study participants (N=619) were randomly assigned to receive omalizumab-igec 300mg, Xolair 300mg, omalizumab-igec 150mg, or Xolair 150mg for 12 weeks.

The cohort included 325 white children (56.4%), with 113 on placebo and 212 on omalizumab; 99 Black children (17.2%), with 30 on placebo and 69 on omalizumab; and 152 children who were Asian ...

Omalizumab was safe and did not cause side effects, other than some instances of minor reactions at the site of injection. This study marks the first time its safety has been assessed in children ...

But omalizumab knocks out a skin test response. I could have somebody who has a huge pricked skin test to dust mite and three months later, gone, which is pretty impressive.

Important early studies had shown that omalizumab held promise for our food allergy patients," the study's senior author, Dr. R. Sharon Chinthrajah, told UPI via email.

Xolair (Omalizumab) Significantly Reduced Nasal Polyps and Congestion Symptoms in Adults with Chronic Rhinosinusitis with Nasal Polyps in Two Phase III Studies ...

A pilot study suggests omalizumab may improve speed, effectiveness, and safety of oral desensitization in children with multiple food allergies; more research is needed to see if effect lasts.

Omalizumab is generally well tolerated in adults and children with allergic asthma. Adverse events most commonly observed are injection-site reaction, viral infection, upper-respiratory-tract ...